These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 29851442)

  • 1. Impact of formulary restrictions on medication intensification in diabetes treatment.
    Stuart BC; Slejko JF; Rueda JD; Cooke CE; Shen X; Roberto P; Ciarametaro M; Dubois R
    Am J Manag Care; 2018 May; 24(5):239-246. PubMed ID: 29851442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of formulary restrictions on medication use and costs.
    Shen X; Stuart BC; Powers CA; Tom SE; Magder LS; Perfetto EM
    Am J Manag Care; 2017 Aug; 23(8):e265-e274. PubMed ID: 29087150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the offer of free prescriptions increase generic prescribing?
    Stuart B; Hendrick F; Dougherty JS; Xu J
    Am J Manag Care; 2017 Jun; 23(6):e193-e201. PubMed ID: 28817295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
    Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
    Stuart B; Hendrick FB; Xu J; Dougherty JS
    Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brand-name prescription drug use among Veterans Affairs and Medicare Part D patients with diabetes: a national cohort comparison.
    Gellad WF; Donohue JM; Zhao X; Mor MK; Thorpe CT; Smith J; Good CB; Fine MJ; Morden NE
    Ann Intern Med; 2013 Jul; 159(2):105-14. PubMed ID: 23752663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare formulary restrictions for glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors used in type 2 diabetes mellitus: 2019-2023.
    Wisniewski B; Smith E; Kaur J; Sherling C; Vanapalli S; Lussier M
    J Manag Care Spec Pharm; 2024 Jan; 30(1):34-42. PubMed ID: 38153863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Restrictions on Antipsychotic Use Differ Between Medicare Part D Stand-Alone Versus Medicare Advantage Plans?
    Chou J; Brandt NJ; Loh FE; Stuart B
    Consult Pharm; 2017 Feb; 32(2):109-118. PubMed ID: 28569663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Coverage Restrictions on Antipsychotic Utilization Among Low-Income Medicare Part D Enrollees.
    Roberto PN; Brandt N; Onukwugha E; Perfetto E; Powers C; Stuart B
    Adm Policy Ment Health; 2017 Nov; 44(6):943-954. PubMed ID: 28660370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.
    Luo J; Feldman R; Rothenberger SD; Hernandez I; Gellad WF
    JAMA Netw Open; 2020 Oct; 3(10):e2020969. PubMed ID: 33057641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
    Sicras-Mainar A; Navarro-Artieda R
    Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.
    Driessen JH; van den Bergh JP; van Onzenoort HA; Henry RM; Leufkens HG; de Vries F
    Diabetes Obes Metab; 2017 Mar; 19(3):421-428. PubMed ID: 27943565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary.
    Feldman WB; Rome BN; Lehmann LS; Kesselheim AS
    JAMA Intern Med; 2020 Apr; 180(4):597-601. PubMed ID: 32011624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.